Literature DB >> 3709025

Pharmacokinetics of (+/-)-, (+)-, and (-)-gossypol in humans and dogs.

D F Wu, Y W Yu, Z M Tang, M Z Wang.   

Abstract

Pharmacokinetic parameters of (+/-)-, (+)-, and (-)-gossypol were determined in humans and dogs after a single oral or intravenous dose. Mean (+/- SD) oral bioavailability of (+/-)-gossypol in dogs was 30.9% +/- 16.2%. Studies in dogs who received single intravenous injections revealed that the elimination t1/2 and volume of distribution of (+)-gossypol were five and six times those of (-)-gossypol, respectively, whereas total body clearance and the AUC of the two enantiomers were similar. Data from men receiving the compounds orally show that the average peak plasma concentration and the AUC of (+)-gossypol are significantly greater than those of the (-)-isomer. The rate constants of alpha, beta, ka, k21, and k10 for (-)-gossypol are significantly greater than those for (+)-gossypol, indicating higher rates of mass transfer of the (-)-species. In humans the elimination t1/2 of (+)-gossypol was 29 times as that of (-)-gossypol, a difference that is more striking than that found in dogs. The elimination t1/2 of (+/-)-gossypol in humans averages 286 +/- 179 hours.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3709025     DOI: 10.1038/clpt.1986.108

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

Review 1.  An overview of the clinical pharmacology and therapeutic potential of gossypol as a male contraceptive agent and in gynaecological disease.

Authors:  D Wu
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

Review 2.  The conduct of drug metabolism studies considered good practice (I): analytical systems and in vivo studies.

Authors:  Xiaodong Liu; Lee Jia
Journal:  Curr Drug Metab       Date:  2007-12       Impact factor: 3.731

3.  Selective inhibition of human immunodeficiency virus type 1 replication by the (-) but not the (+) enantiomer of gossypol.

Authors:  T S Lin; R Schinazi; B P Griffith; E M August; B F Eriksson; D K Zheng; L A Huang; W H Prusoff
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

4.  Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate.

Authors:  L Borgström; L Nyberg; S Jönsson; C Lindberg; J Paulson
Journal:  Br J Clin Pharmacol       Date:  1989-01       Impact factor: 4.335

5.  Gossypol treatment of recurrent adult malignant gliomas.

Authors:  P Bushunow; M M Reidenberg; J Wasenko; J Winfield; B Lorenzo; S Lemke; B Himpler; R Corona; T Coyle
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

6.  A validated HPLC assay for the determination of R-(-)-gossypol in human plasma and its application in clinical pharmacokinetic studies.

Authors:  Hongxia Lin; Murugesan K Gounder; Joseph R Bertino; Ah-Ng Tony Kong; Robert S DiPaola; Mark N Stein
Journal:  J Pharm Biomed Anal       Date:  2012-03-24       Impact factor: 3.935

7.  A preliminary clinical study of gossypol in advanced human cancer.

Authors:  R C Stein; A E Joseph; S A Matlin; D C Cunningham; H T Ford; R C Coombes
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  In vitro and in vivo cytotoxicity of gossypol against central nervous system tumor cell lines.

Authors:  T Coyle; S Levante; M Shetler; J Winfield
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 9.  Systematic Review of Gossypol/AT-101 in Cancer Clinical Trials.

Authors:  Olga Renner; Mascha Mayer; Christian Leischner; Markus Burkard; Alexander Berger; Ulrich M Lauer; Sascha Venturelli; Stephan C Bischoff
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-26

10.  Gossypol toxicity from cottonseed products.

Authors:  Ivana Cristina N Gadelha; Nayanna Brunna S Fonseca; Silvia Catarina S Oloris; Marília M Melo; Benito Soto-Blanco
Journal:  ScientificWorldJournal       Date:  2014-05-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.